Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Leases (2016 - 2025)

Historic Current Leases for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $2.7 million.

  • Summit Therapeutics' Current Leases fell 2827.0% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 2827.0%. This contributed to the annual value of $3.8 million for FY2024, which is 3403.35% up from last year.
  • Summit Therapeutics' Current Leases amounted to $2.7 million in Q3 2025, which was down 2827.0% from $3.1 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Current Leases high stood at $3.8 million for Q3 2024, and its period low was $684000.0 during Q2 2022.
  • In the last 5 years, Summit Therapeutics' Current Leases had a median value of $2.7 million in 2025 and averaged $2.3 million.
  • Per our database at Business Quant, Summit Therapeutics' Current Leases soared by 34517.85% in 2021 and then plummeted by 3200.8% in 2022.
  • Over the past 5 years, Summit Therapeutics' Current Leases (Quarter) stood at $1.1 million in 2021, then soared by 54.9% to $1.7 million in 2022, then surged by 66.21% to $2.8 million in 2023, then skyrocketed by 34.03% to $3.8 million in 2024, then fell by 27.76% to $2.7 million in 2025.
  • Its Current Leases stands at $2.7 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.5 million for Q1 2025.